Factors involved in choosing treatment regimen for relapsed MM
| Disease related | 1. Pace of the disease progression |
| 2. Features of aggressiveness such as extramedullary disease | |
| 3. Circulating plasma cells and/or secondary plasma cell leukemia | |
| 4. Presence or absence of end-organ damage | |
| 5. Bone marrow reserve at the time of relapse | |
| 6. Time to relapse from ASCT | |
| 7. Cytogenetic profile | |
| Treatment related | 1. Induction regimen used |
| 2. Duration and depth of response to prior therapy | |
| 3. ASCT status | |
| 4. Adverse reactions to prior treatment and any residual toxicities | |
| 5. Duration since last effective induction treatment | |
| 6. Availability of novel agents and accessibility to them | |
| Patient related | 1. Functional age of the patient |
| 2. Performance status/frailty | |
| 3. Medical comorbidities | |
| 4. Socioeconomic factors | |
| 5. Patient's health care related goals and preferences |
| Disease related | 1. Pace of the disease progression |
| 2. Features of aggressiveness such as extramedullary disease | |
| 3. Circulating plasma cells and/or secondary plasma cell leukemia | |
| 4. Presence or absence of end-organ damage | |
| 5. Bone marrow reserve at the time of relapse | |
| 6. Time to relapse from ASCT | |
| 7. Cytogenetic profile | |
| Treatment related | 1. Induction regimen used |
| 2. Duration and depth of response to prior therapy | |
| 3. ASCT status | |
| 4. Adverse reactions to prior treatment and any residual toxicities | |
| 5. Duration since last effective induction treatment | |
| 6. Availability of novel agents and accessibility to them | |
| Patient related | 1. Functional age of the patient |
| 2. Performance status/frailty | |
| 3. Medical comorbidities | |
| 4. Socioeconomic factors | |
| 5. Patient's health care related goals and preferences |